Periodic Reporting for period 1 - DNACA (Dementia/Alzheimer Drug Attributed to Cystatin-C and other mutations – precision medicine drug development)

The objective of the project is the development of an effective treatment for rare and common forms of dementia, commencing with a drug addressing Hereditary Cystatin C Amyloid Angiopathy (HCCAA), caused by a genetic mutation, transitioning into other amyloid-induced forms –...